Pfizer Reports 54% Year-Over-Year Revenue Decline in Q2 Amid Sharp Drop in COVID-19 Product Sales

Intelligent Finance APP learned that Pfizer (PFE.US) announced its Q2 2023 financial results on Tuesday. The company's adjusted Q2 profit exceeded expectations, but its revenue fell short due to a sharp decline in the sales of COVID-19 products.

Data shows that Pfizer's Q2 revenue was $12.73 billion, a 54% decrease year-over-year, falling short of the market expectation of $13.27 billion. Revenue excluding the COVID-19 vaccine and the antiviral drug Paxlovid grew by 5%. The total revenue from these products in Q2 was $1.6 billion.

Net profit was $2.33 billion, down from $9.91 billion in the same period last year, with earnings per share at 41 cents compared to $1.73 a year earlier. Adjusted earnings per share were $67, surpassing market expectations of 57 cents.

Looking ahead, Pfizer has narrowed its revenue forecast range for 2023 from the previous $67 billion-$71 billion to $67 billion-$70 billion. The company reiterated its full-year adjusted earnings per share guidance of $3.25-$3.45.

Pfizer's shares have fallen nearly 30% year-to-date, reducing the company's market value to about $203 billion.

Pfizer, Inc. is in a transition phase after the pandemic brought it a period of prosperity. As the world moves past the COVID-19 pandemic, reliance on blockbuster vaccines and treatments that helped combat the virus has decreased, leading to a sharp decline in COVID-related sales this year for the company and its competitors like Moderna (MRNA.US).

This decline has been dragging down Pfizer's sales in the past two quarters, and so far there is no sign of weakening.

However, Pfizer has gradually pinned its hopes on mergers and acquisitions and a record-breaking product pipeline to help the company shift towards new growth areas. Pfizer will hold an earnings call at 10 a.m. EST on Tuesday to provide an update on the company’s latest developments.

Investors are eager for executives to provide updates on several drugs recently launched by Pfizer. Chief Executive Albert Bourla said in May that this would help drive non-Covid product revenue growth at a "faster pace" in the second half of this year.

This includes Pfizer's respiratory syncytial virus vaccine and the latest COVID-19 vaccine, both of which are planned to be launched in the third quarter.

Executives may also be asked about the company's $43 billion acquisition of cancer treatment manufacturer Seagen (SGEN.US) — a deal Pfizer believes will generate over $10 billion in risk-adjusted sales for the company by 2030. However, it is important to note that the U.S. Federal Trade Commission (FTC) is requiring Pfizer and Seagen to provide more information on their proposed merger in the second quarter. This move comes as the agency cracks down on similar deals within the pharmaceutical industry.

Finally, executives may discuss the issue of the tornado hitting Pfizer's main plant in North Carolina. Last month, the company informed hospitals that more than 30 drugs might face new supply disruptions due to the damage caused by the tornado.